Anti-EGFR strategy for colorectal cancer: Searching for the real target

被引：0

作者：

Zaniboni, A. ^{[1
]}

Meriggi, F. ^{[1
]}

机构：

[1] Fdn Poliambulanza, UO Oncol Med, I-25100 Brescia, Italy

来源：

LETTERS IN DRUG DESIGN & DISCOVERY | 2006年 / 3卷 / 08期

关键词：

cetuximalb; colorectal cancer; anti-EGFR therapy;

D O I：

10.2174/157018006778194673

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The epidermal growth factor receptor (EGFR) provides survival signals and is overexpressed in the majority of colorectal cancer. Cetuximab is a recombinant human/mouse monoclonal antibody(MoAb) against EGFR, clinically active in the treatment of human colorectal cancer. Unlike the predictable correlation of response to trastuzumab, another MoAb clinically active in a subgroup of breast cancer patients expressing HER-2/neu, responses to cetuximab in EGFR-expressing colorectal cancer is not predictable.

引用

页码：541 / 543

页数：3

共 50 条

[41] SERS characterization of colorectal cancer cell surface markers upon anti-EGFR treatment [J].

Lyu, Nana ;

Pedersen, Bernadette ;

Shklovskaya, Elena ;

Rizos, Helen ;

Molloy, Mark P. ;

Wang, Yuling .

EXPLORATION, 2022, 2 (03)

[42] Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy [J].

Wei, Shanshan ;

Hu, Wenwei ;

Feng, Jun ;

Geng, Yiting .

CELL COMMUNICATION AND SIGNALING, 2022, 20 (01)

[43] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients [J].

Zlobec, Inti ;

Molinari, Francesca ;

Martin, Vittoria ;

Mazzucchelli, Luca ;

Saletti, Piercarlo ;

Trezzi, Rosangela ;

De Dosso, Sara ;

Vlajnic, Tatjana ;

Frattini, Milo ;

Lugli, Alessandro .

WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (38) :4823-4831

[44] Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients [J].

Inti Zlobec ;

Francesca Molinari ;

Vittoria Martin ;

Luca Mazzucchelli ;

Piercarlo Saletti ;

Rosangela Trezzi ;

Sara De Dosso ;

Tatjana Vlajnic ;

Milo Frattini ;

Alessandro Lugli .

World Journal of Gastroenterology, 2010, 16 (38) :4823-4831

[45] Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer [J].

Sackstein, Paul E. ;

Chintapally, Nikita ;

Wilgucki, Molly ;

Hartley, Marion L. ;

Alqahtani, Ali ;

Weinberg, Benjamin A. .

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (11) :572-583

[46] Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer [J].

Garcia-Saenz, Jose A. ;

Sastre, Javier ;

Diaz-Rubio Garcia, Eduardo .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (11) :737-747

[47] Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road [J].

Rios-Hoyo, Alejandro ;

Monzonis, Xavier ;

Vidal, Joana ;

Linares, Jenniffer ;

Montagut, Clara .

FRONTIERS IN PHARMACOLOGY, 2024, 15

[48] Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy [J].

Shanshan Wei ;

Wenwei Hu ;

Jun Feng ;

Yiting Geng .

Cell Communication and Signaling, 20

[49] Unexpected insights for anti-EGFR cancer therapy [J].

Depeille, Philippe ;

Warren, Robert S. ;

Roose, Jeroen P. .

ONCOTARGET, 2015, 6 (22) :18746-18747

[50] Optimizing Anti-EGFR Strategies in Cancer Treatment [J].

Toschi, Luca ;

Finocchiaro, Giovanna ;

Garassino, Isabella ;

De Vincenzo, Fabio ;

Campagnoli, Elisabetta ;

Ceresoli, Giovanni Luca ;

Cavina, Raffaele ;

Zucali, Paolo Andrea ;

Santoro, Armando ;

Cappuzzo, Federico .

CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) :267-275

← 1 2 3 4 5 →